Please Wait
Applying Filters...
menu
    • menu
    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-23

    Virtual Booth

    An Enquiry

    Menu

    Lansoprazole Takeda Brand

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 86Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amarin licenses Vazkepa to Recordati for Europe
    Amarin licenses Vazkepa to Recordati for Europe

    24 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/24/3104106/18362/en/Amarin-Announces-Exclusive-License-and-Supply-Agreement-with-Recordati-to-Commercialize-VAZKEPA-Icosapent-Ethyl-in-Europe.html

    GLOBENEWSWIRE
    24 Jun 2025
    Share Share
    Amarin Reports First Quarter 2025 Financial Results
    Amarin Reports First Quarter 2025 Financial Results

    07 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/07/3075949/18362/en/Amarin-Reports-First-Quarter-2025-Financial-Results.html

    GLOBENEWSWIRE
    07 May 2025
    Share Share
    Amarin complies with Nasdaq bid price Rule
    Amarin complies with Nasdaq bid price Rule

    29 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/29/3070784/18362/en/Amarin-Regains-Compliance-with-Nasdaq-Minimum-Bid-Price-Requirement.html

    GLOBENEWSWIRE
    29 Apr 2025
    Share Share
    Amarin to Report Q1 2025 Financial Results, Host Call on May 7
    Amarin to Report Q1 2025 Financial Results, Host Call on May 7

    28 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/28/3069658/18362/en/Amarin-to-Report-First-Quarter-2025-Financial-Results-and-Host-Conference-Call-on-May-7-2025.html

    GLOBENEWSWIRE
    28 Apr 2025
    Share Share
    Sebela Pharma Reports Positive Phase 3 Tegoprazan Result in GERD
    Sebela Pharma Reports Positive Phase 3 Tegoprazan Result in GERD

    23 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sebela-pharmaceuticals-announces-positive-topline-results-from-phase-3-triumph-program-of-tegoprazan-in-gerd-302435337.html

    PR NEWSWIRE
    23 Apr 2025
    Share Share
    Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
    Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

    09 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/09/3058308/18362/en/Amarin-Confirms-Effective-Date-for-1-For-20-ADS-Ratio-Change.html

    GLOBENEWSWIRE
    09 Apr 2025
    Share Share